Back to today’s briefing

Story perspectives

Daiichi Sankyo and Merck's Trial Halted Over Safety Concerns

12/20/2025

39 6 Full Breakdown

Summary

Story summary

Daiichi Sankyo and Merck & Co.'s phase 3 trial of I-DXd is on a partial clinical hold due to deaths from grade 5 interstitial lung disease (ILD).
The hold pauses recruitment as the U.S. Food and Drug Administration (FDA) and an independent monitoring committee (IMC) review safety data.
Current patients may continue treatment, but new participants cannot enroll.
The hold could delay data readouts, now projected for fiscal year 2027.

History

Historical Context

The FDA's stricter regulations in 2004 followed the withdrawal of Vioxx, a Merck drug linked to cardiovascular risks, highlighting the need for enhanced safety monitoring in clinical trials. This shift aimed to address concerns over pharmaceutical transparency and patient safety, a trend that continues today, as seen in the current partial clinical hold on I-DXd due to serious adverse effects.

1 of 2

Story summary

Daiichi Sankyo and Merck & Co.'s phase 3 trial of I-DXd is on a partial clinical hold due to deaths from grade 5 interstitial lung disease (ILD).
The hold pauses recruitment as the U.S. Food and Drug Administration (FDA) and an independent monitoring committee (IMC) review safety data.
Current patients may continue treatment, but new participants cannot enroll.
The hold could delay data readouts, now projected for fiscal year 2027.

1 / 2